Bronchiectasis Drugs Market by Product and Geography - Forecast and Analysis 2022-2026

The bronchiectasis drugs market share is expected to increase by USD 276.16 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 9.31%.

This bronchiectasis drugs market research report provides valuable insights into the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers the bronchiectasis drugs market segmentation by product (antibiotics, expectorants, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The bronchiectasis drugs market report also offers information on several market vendors, including AbbVie Inc., Akorn Operating Co. LLC, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Dr. Reddys Laboratories Ltd., Endo International Plc, GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Lupin Ltd, Neopharma Corp., Pfizer Inc., Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Virtus Pharmaceuticals LLC, and Wockhardt Ltd. among others.

What will the Bronchiectasis Drugs Market Size be During the Forecast Period?

Download Report Sample to Unlock the Bronchiectasis Drugs Market Size for the Forecast Period and Other Important Statistics

Bronchiectasis Drugs Market: Key Drivers, Trends, and Challenges

The research studied the historical data considered for years, with 2021 as the base year and 2022 as the estimated year, and produced drivers, trends, and challenges for the global bronchiectasis drugs market.

Key Bronchiectasis Drugs Market Driver

The increasing prevalence of associated risk factors is a key factor driving the global bronchiectasis drugs market growth. Bronchiectasis frequently occurs secondary to other health conditions such as humoral immunodeficiency, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatologic diseases (rheumatoid arthritis and Sjogren's disease), chronic obstructive pulmonary disease (COPD), cystic fibrosis, allergic bronchopulmonary aspergillosis, severe lung infections such as tuberculosis, and pneumonia. The prevalence of these diseases is high across the world. For instance, the prevalence of pneumonia is about 150 people per 10,0000 people globally, and the prevalence of COPD has increased by around 30% globally in the last ten years. Also, more than 70,000 people are living with COPD worldwide. Such a high prevalence of these diseases increases the risk of bronchiectasis. Globally, the prevalence of the health conditions mentioned above is rising largely due to factors such as genetic mutations, environmental changes, rapid modernization, and poor lifestyle habits. Such factors will increase the market growth during the forecast period.

Key Bronchiectasis Drugs Market Trend

Growing awareness about bronchiectasis will fuel the global bronchiectasis drug market growth. Bronchiectasis is often misunderstood as a common cough and cold, as the symptoms of most respiratory tract infections overlap. This results in the infection remaining underdiagnosed, which reduces the chances of proper diagnosis and treatment and hence affects the market growth. The increasing prevalence of the disease requires a greater awareness of the disease across primary and secondary healthcare centers. Therefore, to make people aware of the condition, many awareness programs have been organized by government and non-governmental organizations across the globe. For instance, the World Health Organization (WHO) organizes the Chronic Respiratory Diseases Program to support the Member States in their efforts to reduce the burden of morbidity, disability, and premature mortality related to chronic respiratory diseases. Under this program, WHO takes various initiatives to spread awareness about various respiratory diseases and their subtypes. Such awareness programs about the condition and the medications available for the treatment of bronchiectasis are expected to have a positive impact on the market during the forecast period.

Key Bronchiectasis Drugs Market Challenge

The lack of approved drugs for bronchiectasis is the major challenge to the global bronchiectasis drugs market growth. The treatment options for bronchiectasis consist of medications, CPT (chest physical therapy), the use of devices to clear lung airways, oxygen therapy, and surgery. However, no single treatment works for all people with the condition. The treatment is based on the symptoms of each patient. Most patients with bronchiectasis try different treatments (or combinations of treatments) to get relief from the disease's symptoms. For instance, if bronchiectasis is due to pneumonia, along with antibiotic medication, lung airway devices are also used for thinning and removing the mucus. However, in several cases, the reason for the bronchiectasis infection is different, and hence it needs a broad range of treatment. Currently, the global bronchiectasis drugs market does not have any approved drugs. The drugs prescribed for bronchiectasis include antibiotics, expectorants, bronchodilators, corticosteroids, and mucus-thinning medicines. These drugs have proven their efficacy over symptomatic treatments. However, these drugs are used as OTC and off-label drug therapies largely to relieve the symptoms of other conditions, thus increasing the risk of bronchiectasis. Thus, the lack of approved drug therapies is expected to hinder the growth of the market during the forecast period.

This bronchiectasis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global bronchiectasis drugs market as a part of the global pharmaceuticals market within the overall healthcare industry. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the bronchiectasis drugs market during the forecast period.

Who are the Major Bronchiectasis Drugs Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

• AbbVie Inc.
• Akorn Operating Co. LLC
• Amneal Pharmaceuticals Inc.
• Aurobindo Pharma Ltd.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Cadila Healthcare Ltd.
• Dr. Reddys Laboratories Ltd.
• Endo International Plc
• GlaxoSmithKline Plc
• Hikma Pharmaceuticals Plc
• Lupin Ltd
• Neopharma Corp.
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Virtus Pharmaceuticals LLC
• Wockhardt Ltd.

This statistical study of the bronchiectasis drugs market encompasses successful business strategies deployed by the key vendors. The bronchiectasis drugs market is fragmented, and the vendors are deploying organic and inorganic growth strategies to compete in the market

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments while maintaining their positions in the slow-growing segments.

The report on the global bronchiectasis drugs market contains comprehensive market knowledge and an in-depth vendor landscape add-on to an analysis of the key vendors.

Bronchiectasis Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the bronchiectasis drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the global pharmaceuticals market includes the following core components:

• Inputs
• Inbound logistics
• Operations
• Outbound logistics
• Marketing and sales
• Service
• Support activities
• Innovation

The report has further elucidated other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Bronchiectasis Drugs Market?

For more insights on the market share of various regions Request PDF Sample now!

47% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the bronchiectasis drugs market in North America. Market growth in this region will be faster than the growth of the market in other regions.

The increasing cases of associated risk factors will facilitate the bronchiectasis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID-19 Impact and Recovery Analysis

The COVID-19 pandemic had a negative impact on the growth of the regional bronchiectasis drugs market in 2020. The pandemic led to a decline in the use of bronchiectasis drugs in regional healthcare facilities due to the temporary suspension of most diagnostic services as well as surgical procedures. The pandemic also discouraged patients from visiting healthcare facilities unless it was extremely necessary, thereby impeding the growth of the regional bronchiectasis drugs market in 2020. However, the initiation of COVID-19 vaccination drives in December 2020 and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations in pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. This led to an increase in demand for bronchiectasis drugs from Q1 2021 due to the resumption of regular healthcare services and treatments in North America. Therefore, the regional bronchiectasis drugs market is expected to witness growth during the forecast period.

What are the Revenue-generating Product Segments in the Bronchiectasis Drugs Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

The bronchiectasis drugs market share growth in the antibiotics segment will be significant during the forecast period. The antibiotic segment consists of a wide range of off-label drugs, such as azithromycin, erythromycin, doxycycline, amoxicillin, ciprofloxacin, and macrolides, which are used for the treatment of bronchiectasis. These antibiotics are widely used for treating bronchiectasis, as the condition has no approved drug therapy. Antibiotics play a vital role in the treatment of patients with bronchiectasis by interrupting the vicious infection cycle. They help alleviate inflammation and airway damage caused by bronchiectasis. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the bronchiectasis drugs market size and actionable market insights on the post-COVID-19 impact on each segment.

Request PDF sample

What are the Key Data Covered in this Bronchiectasis Drugs Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive bronchiectasis drugs market growth during the next five years
• Precise estimation of the bronchiectasis drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the bronchiectasis drugs industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of bronchiectasis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch